{"id":"NCT01939002","sponsor":"Biogen","briefTitle":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)","officialTitle":"An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-10","completion":"2015-11","firstPosted":"2013-09-11","resultsPosted":"2017-01-25","lastUpdate":"2017-01-25"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"BIIB017","otherNames":["Plegridy","peginterferon beta-1a","PEGylated interferon beta-1a","PEG IFN β-1a"]},{"type":"DRUG","name":"naproxen","otherNames":["naproxen sodium","Aleve","NSAID","long-acting nonsteroidal anti-inflammatory drug"]}],"arms":[{"label":"BIIB017 plus current FLS therapy","type":"EXPERIMENTAL"},{"label":"BIIB017 plus naproxen","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to determine the proportion of participants with relapsing multiple sclerosis who experience new and/or increased flu-like symptoms (FLS) after transitioning from nonpegylated IFN-β therapies to peginterferon beta-1a (BIIB017).\n\nSecondary objectives are: to determine the severity and frequency (measured by flu-like symptom score \\[FLS-S\\]) of FLS in these participants; to determine the duration (measured in number of hours) of FLS in these participants; to determine the effect of BIIB017 on other participant-reported outcomes, including treatment satisfaction (measured with the Treatment Satisfaction Questionnaire for Medication \\[TSQM\\]) and disability status (measured with the Patient Determined Disease Steps \\[PDDS\\]) over a 56-week period; to determine whether interferon-related FLS result in missed days of work/daily activities (e.g., absenteeism); to assess the use of additional medications (in addition to current medications used to treat FLS) to relieve BIIB017-related FLS; to determine the incidence of adverse events throughout the study period; to characterize the immunogenicity profiles of participants switching from prior IFN-β therapy to BIIB017.","primaryOutcome":{"measure":"Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall Population","timeFrame":"during the first 8 weeks of treatment","effectByArm":[{"arm":"Overall Population","deltaMin":10.3,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":103},"commonTop":["Injection site erythema","Injection site reaction","Influenza like illness","Injection site pruritus","Urinary tract infection"]}}